Agios Pharmaceuticals AGIO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's cash & equivalents?
- Agios Pharmaceuticals (AGIO) reported cash & equivalents of $113.6M in Q1 2026.
- How has Agios Pharmaceuticals's cash & equivalents changed year-over-year?
- Agios Pharmaceuticals's cash & equivalents increased by 43.9% year-over-year, from $78.96M to $113.6M.
- What is the long-term trend for Agios Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's cash & equivalents has grown at a -6.9% compound annual growth rate (CAGR), from $127.44M to $89.13M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.